Want to see XERS full AI Analyst Report?
Xeris Pharmaceuticals (XERS) AI Stock Analysis
Xeris Pharmaceuticals
(NASDAQ:XERS)
The score is driven primarily by improving fundamentals and cash generation (strong operating/free cash flow and high gross margins) and supportive price momentum (clear multi-timeframe uptrend with positive MACD). These positives are tempered by elevated balance-sheet risk (negative equity with meaningful debt) and weak valuation optics from ongoing GAAP losses (negative P/E), despite a generally positive earnings-call outlook with raised/tightened revenue guidance.
Xeris Pharmaceuticals (XERS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.91B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.38M
- Price to Earnings (P/E)
- -107.7
- Beta (1Y)
- 1.10
- Revenue Growth
- 36.33%
- EPS Growth
- 54.68%
- Country
- US
- Employees
- 435
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Xeris Pharmaceuticals Business Overview & Revenue Model
Company Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfo...
How the Company Makes Money
Xeris makes money primarily by selling its FDA-approved prescription medicines. Its key revenue stream is net product revenue generated from U.S. sales of Gvoke, Keveyis, and Recorlev, which are distributed through pharmaceutical channels (e.g., whol...
Xeris Pharmaceuticals Earnings Call Summary
The call emphasized strong commercial momentum (notably Recorlev’s 81% YoY growth), improved profitability (86% gross margin, adjusted EBITDA +50% YoY), strategic wins (Keveyis patent protection, retirement of convertible notes) and material pipeline progress for XP-8121 (multiple patents, Phase III planned by year-end). Lowlights were largely manageable: a one-time non-cash GAAP charge of ~$31M, higher near-term SG&A and R&D investments to fund growth and XP-8121, earlier-year softness in Gvoke that has since rebounded, and some remaining timing/enrollment uncertainty around Phase III. Overall, positive commercial execution and balance sheet actions outweigh the near-term charges and increased investment cadence.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Xeris raised the bottom end of its 2026 total revenue guidance and tightened the range to $385–$390 million (a $5M band), implying roughly 33% growth at the midpoint, backed by strong H1 performance and Q2 results: total revenue $92.1M (up 29% YoY), net product revenue $91M (up 34% YoY), Recorlev $56.8M (up 81% YoY, +$25.3M), Gvoke $22.5M (up ~8% sequentially), and Keveyis $11.7M. Q2 gross margin was ~86% (≈400 bps improvement YoY); Q2 R&D was $10.7M (+$2.6M YoY) and management expects R&D to rise ≈$25M vs. 2025; Q2 SG&A was $61M and full‑year SG&A is now expected to increase ≈$50M vs. 2025 (vs. prior ~$45M guidance). Adjusted EBITDA was $19.3M in Q2 (up $6.7M YoY, >50% growth) and is forecast to increase in absolute dollars for 2026; the company also eliminated $34M of convertible debt (saving ≈$3M annually) while taking a one‑time non‑cash remeasurement charge of ~ $31M in Q2, and expects H2 uplift from Recorlev expansion and seasonal Gvoke demand.
Xeris Pharmaceuticals Financial Statement Overview
Summary
Operating trends are improving with solid TTM revenue ($335.4M, +6.53%) and very strong gross margin (~83%), and cash metrics are strong (TTM operating cash flow $66.5M; free cash flow $64.9M, +37.47%). Offsetting this, balance-sheet risk is significant (negative equity of -$9.7M with $289.4M debt) and TTM net income remains negative (-$17.2M), keeping overall financial quality below top-tier.
Income Statement
56NeutralBalance Sheet
38NegativeCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 335.41M | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M |
| Gross Profit | 279.54M | 238.43M | 166.24M | 135.27M | 87.61M | 36.27M |
| EBITDA | 16.59M | 12.71M | -13.99M | -23.73M | -69.31M | -113.67M |
| Net Income | -17.16M | 554.00K | -54.84M | -62.26M | -94.66M | -122.72M |
Balance Sheet | ||||||
| Total Assets | 411.90M | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M |
| Cash, Cash Equivalents and Short-Term Investments | 121.75M | 111.04M | 71.62M | 72.45M | 121.97M | 102.43M |
| Total Debt | 289.44M | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M |
| Total Liabilities | 421.64M | 369.84M | 352.68M | 329.38M | 299.33M | 209.13M |
| Stockholders Equity | -9.73M | 13.69M | -29.61M | -6.78M | 45.19M | 95.23M |
Cash Flow | ||||||
| Free Cash Flow | 55.38M | 27.93M | -37.85M | -49.29M | -103.42M | -96.62M |
| Operating Cash Flow | 56.61M | 28.63M | -36.98M | -47.02M | -102.89M | -95.53M |
| Investing Cash Flow | -938.00K | -696.00K | 4.88M | -6.00M | 34.46M | 97.96M |
| Financing Cash Flow | 6.69M | 11.39M | 36.17M | -1.61M | 127.47M | 27.25M |
Xeris Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 10.46 is above the 20-day moving average (MA) of 10.46, above the 50-day MA of 9.40, and above the 200-day MA of 7.54, indicating a bullish trend. The MACD of 0.28 indicates Positive momentum. The RSI at 55.04 is Neutral, neither overbought nor oversold. The STOCH value of 28.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksXeris Pharmaceuticals Peers Comparison
Overall Rating
ADMA79Outperform
HRMY77Outperform- XERS64Neutral
PHVS51Neutral
BCRX49Neutral
MNKD46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ADMA | 79Outperform | $2.49B | 13.27 | 39.59% | ― | 8.04% | -18.53% |
| HRMY | 77Outperform | $2.16B | 11.17 | 18.55% | ― | 24.25% | -0.83% |
| XERS | 64Neutral | $1.89B | -107.72 | -426.33% | ― | 36.33% | 54.68% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PHVS | 51Neutral | $2.43B | -11.30 | -61.24% | ― | ― | 9.42% |
| BCRX | 49Neutral | $2.19B | -6.10 | 127.62% | ― | 68.72% | -737.08% |
| MNKD | 46Neutral | $1.20B | -28.17 | 78.60% | ― | 30.46% | -223.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XERS | Xeris Pharmaceuticals | 10.46 | 2.75 | 35.67% | |
| BCRX | BioCryst Pharmaceuticals | 8.24 | 1.21 | 17.21% | |
| MNKD | MannKind Corporation | 3.93 | -1.77 | -31.05% | |
| ADMA | ADMA Biologics Inc | 10.48 | -3.55 | -25.30% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 34.41 | 3.47 | 11.23% | |
| PHVS | Pharvaris N.V. | 34.33 | 12.53 | 57.48% |
Xeris Pharmaceuticals Corporate Events
Xeris Pharmaceuticals Expands Board with New Independent Director
PositiveOn November 2, 2026, Xeris expanded its Board of Directors from eight to nine members and appointed Menassie Taddese as a Class II director, with his term running through the 2029 annual meeting. Taddese also joined the Audit Committee and was determ...
Xeris Pharmaceuticals Files Patent Suits to Protect KEVEYIS
PositiveOn October 13, 2026, Xeris Pharmaceuticals filed two patent infringement lawsuits in the U.S. District Court for the District of New Jersey against Torrent Pharma-affiliated entities, Cycle Pharmaceuticals, Lemed Pharmacy entities, and Rising Pharma-...
Xeris Highlights XP-8121 Strategy and Growth Roadmap
PositiveOn September 9, 2026, Xeris Biopharma hosted an XP‑8121 program overview to outline its strategy for becoming what it calls the next great biopharmaceutical company. Executives highlighted strong commercial performance from Recorlev, Gvoke and...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 02, 2026